Abstract
In the absence of effective treatment, infection with the human immunodeficiency virus (HIV) ultimately leads to the acquired immune deficiency syndrome (AIDS). Many attempts have been made to prevent and attenuate HIV infection. While antiretroviral therapies for infected individuals have had great success, preventative and therapeutic vaccines focused on both humoral and cell-mediated immunity have failed. Recently, several natural killer cell receptor (NKR) genotypes, in concert with certain class I human histompatibility-linked antigens (HLA) were found to be associated with protection from HIV infection and/or disease progression. These receptors are expressed on both natural killer (NK) cells and subsets of T lymphocytes. As HIV infection is often associated with attenuation of NK cells and much remains unknown about the basic functions of NKR, it remains undetermined whether the protective effect of these receptors relates to their expression on NK cells, T lymphocytes or both. This review summarizes current literature regarding NKR and HIV infection, and addresses several major questions remaining about the role of these receptors in protection against infection and disease progression.
Keywords: NK cells, HIV, T lymphocytes, NK receptors, AIDS
Current HIV Research
Title: Natural Killer Cell Receptors in Human Immunodeficiency Virus Infection: Pathways to Protection or Doors to Disappointment?
Volume: 7 Issue: 5
Author(s): Matthew S. Parsons and Michael Grant
Affiliation:
Keywords: NK cells, HIV, T lymphocytes, NK receptors, AIDS
Abstract: In the absence of effective treatment, infection with the human immunodeficiency virus (HIV) ultimately leads to the acquired immune deficiency syndrome (AIDS). Many attempts have been made to prevent and attenuate HIV infection. While antiretroviral therapies for infected individuals have had great success, preventative and therapeutic vaccines focused on both humoral and cell-mediated immunity have failed. Recently, several natural killer cell receptor (NKR) genotypes, in concert with certain class I human histompatibility-linked antigens (HLA) were found to be associated with protection from HIV infection and/or disease progression. These receptors are expressed on both natural killer (NK) cells and subsets of T lymphocytes. As HIV infection is often associated with attenuation of NK cells and much remains unknown about the basic functions of NKR, it remains undetermined whether the protective effect of these receptors relates to their expression on NK cells, T lymphocytes or both. This review summarizes current literature regarding NKR and HIV infection, and addresses several major questions remaining about the role of these receptors in protection against infection and disease progression.
Export Options
About this article
Cite this article as:
Parsons S. Matthew and Grant Michael, Natural Killer Cell Receptors in Human Immunodeficiency Virus Infection: Pathways to Protection or Doors to Disappointment?, Current HIV Research 2009; 7 (5) . https://dx.doi.org/10.2174/157016209789346273
DOI https://dx.doi.org/10.2174/157016209789346273 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Tumor-Associated Antigens to the MHC Class I Presentation Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets HIV-1 (co)Receptors: Implications for Vaccine and Therapy Design
Current Pharmaceutical Design A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets Endostatin: Preclinical Development as an Anticancer Agent
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Current Pharmaceutical Design AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Transforming Growth Factor-β: A Molecular Target for the Future Therapy of Glioblastoma
Current Pharmaceutical Design Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1
Current Gene Therapy Local Gene Delivery for Cancer Therapy
Current Gene Therapy Efficacy and Tolerability of Vinorelbine in the Cancer Therapy
Current Drug Safety Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
Current Cancer Drug Targets Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates
Cardiovascular & Hematological Disorders-Drug Targets Helicase Domain Containing Proteins in Human Disorders
Current Genomics 1,2,4-Triazine Chemistry Part III: Synthetic Strategies to Functionalized Bridgehead Nitrogen Heteroannulated 1,2,4-Triazine Systems and their Regiospecific and Pharmacological Properties
Current Organic Synthesis Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
Current Cancer Drug Targets